EA202192726A1 - Magea1-специфические т-клеточные рецепторы и их использование - Google Patents
Magea1-специфические т-клеточные рецепторы и их использованиеInfo
- Publication number
- EA202192726A1 EA202192726A1 EA202192726A EA202192726A EA202192726A1 EA 202192726 A1 EA202192726 A1 EA 202192726A1 EA 202192726 A EA202192726 A EA 202192726A EA 202192726 A EA202192726 A EA 202192726A EA 202192726 A1 EA202192726 A1 EA 202192726A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tcr
- magea1
- specific
- usage
- cell receptors
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 abstract 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к выделенному T-клеточному рецептору (TCR), специфическому к MAGEA1-производному пептиду, и к полипептиду, содержащему функциональную часть TCR. Также рассматривается поливалентный комплекс TCR, нуклеиновая кислота, кодирующая TCR, клетка, экспрессирующая TCR, и фармацевтическая композиция, содержащая TCR. Изобретение также относится к TCR для использования в качестве лекарственного средства, в частности к TCR для использования при лечении рака.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19167440 | 2019-04-04 | ||
PCT/EP2020/059193 WO2020201318A1 (en) | 2019-04-04 | 2020-04-01 | Magea1 specific t cell receptors and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192726A1 true EA202192726A1 (ru) | 2022-01-26 |
Family
ID=66101858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192726A EA202192726A1 (ru) | 2019-04-04 | 2020-04-01 | Magea1-специфические т-клеточные рецепторы и их использование |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230037552A1 (ru) |
EP (1) | EP3947435A1 (ru) |
JP (1) | JP7483746B2 (ru) |
CN (1) | CN113840834A (ru) |
AU (1) | AU2020255249A1 (ru) |
CA (1) | CA3135306A1 (ru) |
EA (1) | EA202192726A1 (ru) |
TW (1) | TW202102530A (ru) |
WO (1) | WO2020201318A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230310607A1 (en) | 2021-11-09 | 2023-10-05 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
WO2023232111A1 (zh) * | 2022-06-01 | 2023-12-07 | 北京可瑞生物科技有限公司 | Mage-a1特异性tcr及其用途 |
EP4328239A1 (en) * | 2022-08-26 | 2024-02-28 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Immunotherapeutics based on magea1-derived epitopes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
HUE038833T2 (hu) | 2005-08-05 | 2018-11-28 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Antigénspecifikus T-sejtek létrehozása |
EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
JP6639233B2 (ja) * | 2013-01-29 | 2020-02-05 | マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン(エムディーシー) ベルリン−ブッフ | Mage−a1を認識する高結合活性結合分子 |
CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
AU2018234830B2 (en) | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
-
2020
- 2020-03-31 TW TW109110997A patent/TW202102530A/zh unknown
- 2020-04-01 CN CN202080036468.XA patent/CN113840834A/zh active Pending
- 2020-04-01 JP JP2021558921A patent/JP7483746B2/ja active Active
- 2020-04-01 EP EP20713920.5A patent/EP3947435A1/en active Pending
- 2020-04-01 AU AU2020255249A patent/AU2020255249A1/en active Pending
- 2020-04-01 EA EA202192726A patent/EA202192726A1/ru unknown
- 2020-04-01 US US17/600,518 patent/US20230037552A1/en active Pending
- 2020-04-01 WO PCT/EP2020/059193 patent/WO2020201318A1/en unknown
- 2020-04-01 CA CA3135306A patent/CA3135306A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020255249A1 (en) | 2021-10-28 |
WO2020201318A1 (en) | 2020-10-08 |
EP3947435A1 (en) | 2022-02-09 |
TW202102530A (zh) | 2021-01-16 |
CN113840834A (zh) | 2021-12-24 |
JP7483746B2 (ja) | 2024-05-15 |
CA3135306A1 (en) | 2020-10-08 |
US20230037552A1 (en) | 2023-02-09 |
JP2022527813A (ja) | 2022-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202192327A1 (ru) | T-клеточные рецепторы, специфичные к mage-a4 | |
EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
EA202192726A1 (ru) | Magea1-специфические т-клеточные рецепторы и их использование | |
EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
EA201991696A1 (ru) | Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения | |
BR112016027805A2 (pt) | receptores de células t do anti-papilomavírus humano 16 e7 | |
EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
MX2021001837A (es) | Constructos del receptor de celulas t y usos de los mismos. | |
EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
EA201792084A1 (ru) | Способы и композиции, связанные с полипептидами - агонистами gpcr | |
EA201992536A1 (ru) | Tcr и пептиды | |
BR112018075649A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo | |
EA202192024A1 (ru) | Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
EA202092589A3 (ru) | Cxcr2-связывающие полипептиды | |
BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
EA202091577A1 (ru) | Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител | |
EA201500506A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a |